查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129011

質體DNA生產市場：依等級、研發階段、應用、疾病、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Plasmid DNA Manufacturing Market, By Grade, By Development Phase, By Application, By Disease, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 361 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，質體DNA 生產市場價值將達到 24.7852 億美元，並將在 2026 年至 2033 年期間以 17.98% 的複合年成長率成長。

質體DNA生產是指利用受控的生物學和純化製程生產質體，質粒是一種具有環狀結構的雙鏈DNA分子。質體DNA主要用於基因治療、DNA疫苗、細胞和基因治療、重組蛋白等研究。質體DNA生產過程包括質體設計和克隆、轉化到大腸桿菌等細菌、發酵擴增質體數量、收穫、細胞裂解、DNA純化以及檢測和品管。然而，對於臨床和商業應用，生產過程必須在GMP條件下進行，以確保所生產的質體DNA符合指定的品質標準。

質體DNA生產市場－市場動態

基因和細胞療法研發管線的不斷拓展正在推動市場成長。

基因和細胞療法研發管線的快速擴張是質體DNA生產市場的主要驅動力。質體DNA是多種病毒載體（包括腺相關病毒（AAV）和慢病毒載體）生產過程中的關鍵成分，也直接用於某些基因療法。根據Cogentia預測，截至2024年底，基因療法研發管線將包括約1424個臨床前候選藥物、341個I期候選藥物、306個II期候選藥物和35個III期候選藥物，這意味著許多計畫將進入臨床和商業化生產階段。隨著這些療法推進到臨床試驗階段，研發公司將需要越來越多的高品質、符合GMP標準的質體DNA。

預計2025年的主要在研計畫將成為質體DNA生產市場的關鍵驅動力。 Vertex Pharmaceuticals公司的CASGEVY（exagamglogene autotemcel）是一種領先的基因編輯療法，而Sarepta Therapeutics公司的ELEVIDYS（delandistrogene moxeparvovec）是一種已上市的基於腺相關病毒（AAV）的療法。兩者均列入FDA已通過核准的細胞和基因治療產品清單。隨著這些療法的不斷推進，下游對用於病毒載體生產過程的質體DNA的需求也將隨之成長。

質體DNA生產市場－市場區隔分析：

全球質體DNA生產市場按等級、開發階段、應用、疾病和地區進行細分。

依研發階段，市場可分為三類：臨床前治療藥物、已上市治療藥物及臨床階段治療藥物。預計臨床階段治療藥物領域將在質體DNA生產市場實現顯著的收入成長。該領域強勁的收入前景主要歸功於越來越多的候選治療藥物進入臨床前研發階段，隨後推進至I-III期臨床試驗。用於基因治療生產過程的臨床級質體在病毒載體生產、基因編輯或作為直接治療成分方面的需求日益成長。對品管、符合GMP規範的質體DNA的需求不斷成長，也與後期臨床試驗中使用的質體的穩定、大規模生產需求不斷成長密切相關。

根據疾病類型，市場可分為四大類：遺傳性疾病、癌症、感染疾病和其他疾病。預計癌症領域將實現最高的收入成長。這一顯著的收入成長主要得益於質體DNA在癌症基因治療、細胞治療、病毒載體生產和DNA癌症疫苗等領域的日益普及。質體DNA是病毒載體生產和現代腫瘤學中細胞基因改造的關鍵起始材料。製藥和生物技術公司在癌症領域基因治療和細胞治療產品線的擴展，推動了對高純度、符合GMP標準的質體DNA的需求。隨著候選藥物從臨床前研究進入臨床試驗和商業化生產階段，這種需求尤其旺盛。個人化和標靶癌症療法的日益普及也進一步促進了這項需求。

質體DNA生產市場－區域分析

北美市場佔據主導地位。推動市場成長要素之一是癌症負擔日益加重，以及人們對基因療法、細胞療法、癌症疫苗和其他新型生物製藥日益成長的興趣，這些療法均以質體DNA為關鍵生產原料。美國國家癌症研究所 (NCI) 預計，到2025年，美國將新增2,041,910例癌症病例，並有618,120例癌症死亡病例。同時，加拿大癌症統計局預計，到2025年，加拿大將新增254,800例癌症病例，並有87,400例癌症死亡病例。如此巨大的癌症負擔正促使製藥和生物技術公司擴大其基因和細胞療法的研發管線，專門用於癌症治療，從而導致對用於病毒載體和基因工程生產的高純度、GMP級質體DNA的需求增加。

美國質體DNA生產市場—國家分析

美國佔了大部分市場佔有率。推動這一成長的主要因素之一是領先的製藥和生物技術公司對基因和細胞療法的研發和生產的大規模投資，這帶動了對病毒載體和高品質質體DNA（基因工程的關鍵組成部分）的需求成長。例如，諾華公司於2025年4月宣布，將在未來五年內投資230億美元用於其在美國的生產和研發設施，包括擴大產能以支持先進療法。該公司在美國的業務網路已包括位於北卡羅來納州達勒姆的基因療法生產工廠。

目錄

第1章：質體DNA生產市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：質體DNA生產的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：質體DNA製造業的分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：質體DNA生產市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：質體DNA生產市場現狀

  • 質體DNA生產市佔分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章質體DNA生產市場：依等級分類

  • 概述
    • 按等級分類的市佔率分析
    • 研發級
      • 病毒載體的開發
      • AAV
      • 慢病毒
      • 腺病毒
      • 逆轉錄病毒
      • 其他
      • mRNA發育
      • 抗體生成
      • DNA疫苗的研發
      • 其他
    • GMP級

第8章質體DNA生產市場：依發展階段分類

  • 概述
    • 基於細分市場的市佔率分析：依發展階段分類
    • 臨床前治療
    • 非處方藥
    • 臨床給藥藥物

第9章質體DNA生產市場：依應用分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • DNA疫苗
    • 免疫療法
    • 細胞和基因治療
    • 其他

第10章質體DNA生產市場：依疾病分類

  • 概述
    • 基於細分市場的市佔率分析：依疾病分類
    • 遺傳性疾病
    • 癌症
    • 感染疾病
    • 其他

第11章質體DNA生產市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：質體DNA製造業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Lonza
    • Charles River Laboratories
    • Thermo Fisher Scientific
    • AGC Biologics
    • GenScript ProBio
    • Aldevron（Danaher）
    • Cobra Biologics（Charles River）
    • Catalent
    • WuXi AppTec
    • WuXi Advanced Therapies
    • Eurogentec
    • Sartorius（BIA Separations）
    • PharmaCell
    • ProBio
    • Pharmaron
    • Esco Aster
    • AGTC（Applied Genetic Technologies Corp.）
    • VGXI（GeneOne Life Science）
    • PlasmidFactory
    • VectorBuilder
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7335

Plasmid DNA Manufacturing Market size was valued at US$ 2,478.52 Million in 2025, expanding at a CAGR of 17.98% from 2026 to 2033.

Plasmid DNA Manufacturing means the production of plasmids, which are DNA molecules in the form of circles of double-stranded DNA, by means of controlled biological and purification processes. Plasmid DNA is mostly produced for gene therapy, DNA vaccination, cell and gene therapy, recombinant proteins, and another research. The process of plasmid DNA manufacturing includes plasmid design and cloning, transformation of bacteria such as Escherichia coli and fermentation to increase the number of plasmids, harvesting, cell lysis, DNA purification, and testing and quality control. However, for clinical and commercial application, the process of manufacturing is carried out under GMP conditions to ensure compliance with the needed quality of the produced plasmid DNA.

Plasmid DNA Manufacturing Market- Market Dynamics

Growing gene and cell therapy pipeline drives market growth

The rapid expansion of gene and cell therapy pipelines is a major driver for the plasmid DNA manufacturing market. Plasmid DNA is an essential component in the manufacturing process of several viral vectors, including AAV and lentiviral vectors and is also used directly in some gene therapies. By the end of 2024, the gene-therapy pipeline contained approximately 1,424 preclinical candidates, 341 Phase I candidates, 306 Phase II candidates, and 35 Phase III candidates, suggesting there is a large pool of programs that will be entering clinical and commercial manufacturing, according to the Cogentia. As these therapies progress through the clinical phases, developers require increasing quantities of high-quality and GMP-grade plasmid DNA.

Leading pipeline programs in 2025 will be important drivers for the plasmid DNA manufacturing market. Vertex Pharmaceuticals's CASGEVY (exagamglogene autotemcel) is a major gene-editing therapy, while Sarepta Therapeutics's ELEVIDYS (delandistrogene moxeparvovec) represents a commercial AAV-based therapy; both are included in the FDA's list of approved cellular and gene therapy products. As such therapies continue to progress, there will be downstream requirements for plasmid DNA for use in the manufacturing process of viral vectors.

Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Plasmid DNA Manufacturing Market is segmented on the basis of grade, development phase, application, disease, and Region.

The market is divided into three categories based on development phase: Pre-Clinical Therapeutics, Marketed Therapeutics and Clinical Therapeutics. The Clinical Therapeutics sector is expected to observe significant revenue growth in the Plasmid DNA Manufacturing market. The strong revenue outlook of the segment is primarily attributed to the rising number of therapeutic candidates entering pre-clinical development and subsequently progressing towards phase I-III clinical trials. Clinical grade plasmids, which are used in the manufacturing process of gene therapies, are increasingly in demand in connection with the production of viral vectors, gene-editing, or as a direct therapeutic moiety. The greater need for plasmid DNA of higher quality and compliance (GMP) is also linked to the greater need for consistent and large-scale production of plasmids for use in later-stage clinical trials.

The market is divided into four categories based on disease: Genetic Disorder, Cancer, Infectious Disease and Others. The Cancer segment would witness the highest revenue growth. The significant revenue growth is driven by the rising adoption of plasmid DNA in cancer gene treatments, cell therapies, viral-vector production and DNA-based cancer vaccinations. Plasmid DNA is a key starting material for the production of viral vectors and for the genetic modification of cells utilized in modern oncology therapies. The demand for high-purity and GMP-grade plasmid DNA is being driven by the growth of gene and cell therapy pipelines in the cancer area by pharmaceutical and biotechnology companies, especially as candidates move from pre-clinical research to clinical and commercial manufacture. This demand is also being fueled by rising use of tailored and targeted cancer medicines.

Plasmid DNA Manufacturing Market- Geographical Insights

North America dominates the market. One of the major growth drivers is the high and increasing cancer burden and growing interest in gene treatments, cell therapies, cancer vaccines and other novel biotherapeutics that use plasmid DNA as a critical input in their production process. In 2025, the National Cancer Institute estimates there will be 2,041,910 new cancer cases and 618,120 cancer deaths in the United States. Meanwhile, Canadian Cancer Statistics predicts that there will be 254,800 new cancer cases and 87,400 cancer deaths in Canada in 2025. This huge cancer burden is making pharmaceutical and biotech companies to ramp up their oncology focused gene and cell therapy pipeline which in turn is driving the requirement for high purity and GMP-grade plasmid DNA for manufacturing viral vectors and genetic engineering.

US Plasmid DNA Manufacturing Market- Country Insights

The US holds a majority of market share. One of the major drivers for this growth is the huge investment made by the leading pharmaceutical and biotech companies in development and manufacturing of gene and cell therapy which is leading to an increasing demand for high-quality plasmid DNA as a critical component in the production of viral vectors and genetic engineering. For instance, Novartis announced in April 2025 that it would invest $23 billion over five years in its U.S. manufacturing and research and development footprint including expanding capabilities supporting advanced therapies. Its U.S. network already includes a gene-therapy manufacturing facility in Durham, North Carolina.

Plasmid DNA Manufacturing Market- Competitive Landscape:

Plasmid DNA manufacturing market is moderately consolidated with several key players and highly competitive, with competition focused on GMP manufacturing capacity, scale, quality of products, regulatory know-how, turn around time and end-to-end services. Key players include Charles River Laboratories, Danaher (Aldevron), Lonza, Thermo Fisher Scientific, GenScript ProBio, VGXI, Catalent, AGC Biologics, WuXi AppTec, Eurogentec, Kaneka, VectorBuilder.

Recent Developments:

In August 2026, 4basebio PLC, a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA(R) development and clinical programs. Through the collaboration, Genezen will offer access to 4basebio's synthetic DNA developed specifically for viral vector applications, creating a more streamlined path for cell and gene therapy developers to advance programs toward the clinic.

In January 2026, Bionova Scientific LLC, an Asahi Kasei company and a bespoke CDMO, has announced a strategic manufacturing alliance with Syenex, a genetic medicines platform company. The collaboration is focused on expanding global access to plasmid DNA used in next-generation gene delivery for advanced cell and gene therapies. Under the agreement, Bionova Scientific will serve as the preferred manufacturing partner for Syenex's delivery platforms. The partnership builds on Bionova's plasmid DNA manufacturing capabilities, which support lentiviral vector production and DNA templates for mRNA manufacturing. The companies said the alliance addresses ongoing challenges in pricing, quality, and supply-chain reliability of plasmid DNA.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • AGC Biologics
  • GenScript ProBio
  • Aldevron (Danaher)
  • Cobra Biologics (Charles River)
  • Catalent
  • WuXi AppTec
  • WuXi Advanced Therapies
  • Eurogentec
  • Sartorius (BIA Separations)
  • PharmaCell
  • ProBio
  • Pharmaron
  • Esco Aster
  • AGTC (Applied Genetic Technologies Corp.)
  • VGXI (GeneOne Life Science)
  • PlasmidFactory
  • VectorBuilder
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY GRADE- MARKET ANALYSIS, 2020 - 2033

  • R&D Grade
  • Viral Vector Development
  • AAV
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Others
  • mRNA Development
  • Antibody Development
  • DNA Vaccine Development
  • Others
  • GMP Grade

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DEVELOPMENT PHASE- MARKET ANALYSIS, 2020 - 2033

  • Pre-Clinical Therapeutics
  • Marketed Therapeutics
  • Clinical Therapeutics

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • DNA Vaccines
  • Immunotherapy
  • Cell & Gene Therapy
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033

  • Genetic Disorder
  • Cancer
  • Infectious Disease
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Plasmid DNA Manufacturing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Plasmid DNA Manufacturing Market Snippet by Grade
    • 2.1.2. Plasmid DNA Manufacturing Market Snippet by Development Phase
    • 2.1.3. Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.4. Plasmid DNA Manufacturing Market Snippet by Disease
    • 2.1.5. Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.6. Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2. Competitive Insights

3. Plasmid DNA Manufacturing Key Market Trends

  • 3.1. Plasmid DNA Manufacturing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Plasmid DNA Manufacturing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Plasmid DNA Manufacturing Market Opportunities
  • 3.4. Plasmid DNA Manufacturing Market Future Trends

4. Plasmid DNA Manufacturing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Plasmid DNA Manufacturing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Plasmid DNA Manufacturing Market Landscape

  • 6.1. Plasmid DNA Manufacturing Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Plasmid DNA Manufacturing Market - By Grade

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Grade, 2025 & 2033 (%)
    • 7.1.2. R&D Grade
      • 7.1.2.1. Viral Vector Development
      • 7.1.2.1.1. AAV
      • 7.1.2.1.2. Lentivirus
      • 7.1.2.1.3. Adenovirus
      • 7.1.2.1.4. Retrovirus
      • 7.1.2.1.5. Others
      • 7.1.2.2. mRNA Development
      • 7.1.2.3. Antibody Development
      • 7.1.2.4. DNA Vaccine Development
      • 7.1.2.5. Others
    • 7.1.3. GMP Grade

8. Plasmid DNA Manufacturing Market - By Development Phase

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Development Phase, 2025 & 2033 (%)
    • 8.1.2. Pre-Clinical Therapeutics
    • 8.1.3. Marketed Therapeutics
    • 8.1.4. Clinical Therapeutics

9. Plasmid DNA Manufacturing Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 9.1.2. DNA Vaccines
    • 9.1.3. Immunotherapy
    • 9.1.4. Cell & Gene Therapy
    • 9.1.5. Others

10. Plasmid DNA Manufacturing Market - By Disease

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
    • 10.1.2. Genetic Disorder
    • 10.1.3. Cancer
    • 10.1.4. Infectious Disease
    • 10.1.5. Others

11. Plasmid DNA Manufacturing Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Plasmid DNA Manufacturing Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Plasmid DNA Manufacturing Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Lonza
    • 12.2.2. Charles River Laboratories
    • 12.2.3. Thermo Fisher Scientific
    • 12.2.4. AGC Biologics
    • 12.2.5. GenScript ProBio
    • 12.2.6. Aldevron (Danaher)
    • 12.2.7. Cobra Biologics (Charles River)
    • 12.2.8. Catalent
    • 12.2.9. WuXi AppTec
    • 12.2.10. WuXi Advanced Therapies
    • 12.2.11. Eurogentec
    • 12.2.12. Sartorius (BIA Separations)
    • 12.2.13. PharmaCell
    • 12.2.14. ProBio
    • 12.2.15. Pharmaron
    • 12.2.16. Esco Aster
    • 12.2.17. AGTC (Applied Genetic Technologies Corp.)
    • 12.2.18. VGXI (GeneOne Life Science)
    • 12.2.19. PlasmidFactory
    • 12.2.20. VectorBuilder
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us